

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
21-688

STATISTICAL REVIEW(S)



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Pharmacoepidemiology and Statistical Science
Office of Biostatistics

STATISTICAL REVIEW AND EVALUATION CLINICAL STUDIES

NDA/Serial Number: 21-688

Drug Name: SENSIPAR (cinacalcet HCl)

Indication(s): ——— treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease, receiving or not receiving dialysis.
Treatment of hypercalcemia in patients with parathyroid carcinoma, or in patients with primary hyperparathyroidism for whom parathyroidectomy is not a treatment option.

Applicant: Amgen

Date(s): Submitted 9/5/03. PDUFA due date 3/8/04

Review Priority: Priority

Biometrics Division: Division of Biometrics 2 (HFD-715)

Statistical Reviewer: Joy Mele, M.S.

Concurring Reviewers: Todd Sahlroot, Ph.D. (Team Leader)
Ed Nevius, Ph.D. (Division Director)

Medical Division: Division of Metabolic and Endocrine Drug Products (HFD-510)

Clinical Team: Theresa Kehoe, M.D. (Medical Reviewer)
Patricia Beaston, M.D. (Medical Reviewer)
Eric Colman, M.D. (Team Leader)
David Orloff, M.D. (Division Director)

Project Manager: Randy Hedin

Keywords: NDA review, Clinical studies, Safety analyses

1. EXECUTIVE SUMMARY OF STATISTICAL FINDINGS	4
1.1 Conclusions and Recommendations	4
1.2 Brief Overview of Clinical Studies	7
1.2.1 Primary Hyperparathyroidism	7
1.2.2 Secondary Hyperparathyroidism	7
1.3 Statistical Issues	10
2. INTRODUCTION	11
2.1 Overview	11
2.2 Data Sources	11
3. STATISTICAL EVALUATION	11
3.1 Evaluation of Efficacy	11
3.1.1 Primary Hyperphosphotemia.....	11
3.1.2 Secondary Hyperphosphotemia in Patients with End Stage Renal Disease.....	18
3.1.2.1 Phase 2 Studies 990101, 990102 and 990740	18
3.1.2.2 Phase 3 Studies 20000172, 20000183 and 20000188	20
Design	20
Sterols	21
Patient Disposition	22
Baseline Demographics.....	24
Dosing	26
Statistical Methods	26
Efficacy Results	26
3.1.3 Secondary Hyperphosphotemia in Patients with Chronic Renal Insufficiency.....	30
3.1.4 Extension Study 20010240 in Patients with Secondary HPT.....	36
3.1.5 Oversuppression of iPTH.....	39
3.1.6 Bio intact PTH versus intact PTH.....	41
3.2 Evaluation of Safety	43
4. FINDINGS IN SPECIAL/SUBGROUP POPULATIONS	44
4.1 Gender, Race and Age.....	44
4.2 Subgroup Populations Defined by Baseline Characteristics	44
5. SUMMARY AND CONCLUSIONS	46
5.1 Conclusions and Recommendations	46
5.2 Labeling recommendations and comments.....	49

Appendix 1. Study 20000159 calcium and daily dose graphed by patient 50
Appendix 2. Study 20000204 calcium and daily dose graphed by patient 53
Appendix 3. Histogram and cumulative distribution plots of baseline iPTH (pg/mL) by protocol 54
Appendix 4. iPTH (pg/mL) by week for Study 183 with reference lines at 250, 150 and 100 pg/mL..... 55
**Appendix 5. iPTH (pg/mL) with reference lines at 250, 150 and 100 pg/mL by original protocol and by week
for Extension Study 240 56**
**Appendix 6. Number of times iPTH (pg/mL) under 100 or 150 pg/mL during the last 6 visits on study (Weeks
16-26) for Studies 172, 183 and 188 combined 57**

APPEARS THIS WAY
ON ORIGINAL

1. EXECUTIVE SUMMARY OF STATISTICAL FINDINGS

1.1 Conclusions and Recommendations

The applicant's proposed indications for cinacalcet (sensipar) are the following:

- Treatment of hypercalcemia in patients with primary hyperparathyroidism or with parathyroid carcinoma
- Treatment of secondary hyperparathyroidism
- Control of parathyroid hormone (PTH), serum calcium x phosphorus, phosphorus and calcium levels in patients with chronic kidney disease receiving or not receiving dialysis

With regard to primary hyperparathyroidism, this reviewer has the following comments and conclusions based on this statistical review:

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

No assessment of safety can be made just based on 990120 since clearly patients with serious ADE's in 980125 would not continue into 990120.

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

With regard to secondary hyperparathyroidism in patients with ESRD and receiving dialysis, this reviewer has the following comments and conclusions based on this statistical review:

- Three Phase 2 studies showed that doses above 50 mg per day are usually needed to significantly impact PTH particularly in patients with baseline PTH above about 525.
- In the three large Phase 3 studies (172, 183 and 188), about 39% had mild HPT

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.